Megan Sanders, Chief Executive Officer at Thoracic Oncology Group of Australasia, shared a post on LinkedIn:
“At the Thoracic Oncology Group of Australasia (TOGA) International Conference Symposium this evening, A/Prof Venessa Chin shared some exciting new directions in lung cancer treatment — from bispecific antibodies to smarter use of immunotherapy before surgery.
HARMONI-6: This Phase III trial looked at a new bispecific antibody, ivonescimab, which targets both VEGF and PD-1 in a Stage IIIB-IV squamous NSCLC population with no prior systemic therapy. When combined with chemotherapy, it almost doubled median progression-free survival (11.1 vs 6.9 months) compared with a PD-1 inhibitor plus chemo. The benefit was seen across all PD-L1 subgroups, though VEGF-related side effects still need watching. While the study was conducted in a Chinese cohort, it signals real promise for bispecifics in squamous NSCLC.
DeLLphi-303: In extensive-stage small cell lung cancer, the DLL3-targeted bispecific tarlatamab was examined in the 1L setting with chemo and immunotherapy. With a median PFS of 10.3 months, it appears to enhance immune activation and sustain response — potentially paving the way for new combination strategies in this difficult-to-treat disease.
MDT Bridge: This Phase II study explored whether neoadjuvant immunotherapy + chemotherapy can turn borderline-resectable Stage IIB- IIIB NSCLC participants into surgical candidates. The answer may well be yes — 82% of borderline cases became operable, and 95% of resectable cases stayed that way after treatment. For those who can’t proceed to surgery, ongoing durvalumab after chemoradiation remains an option.
It’s worth checking out our entire event for thoracic cancer highlights from ESMO, ASTRO and iMiG.
If you register, you will receive a personalised link to your inbox. If registrations have closed, you should be able to access the recording at the same link.
Check out our other educational events at our YouTube channel.”
More posts featuring Thoracic Oncology Group of Australasia.
